25 XP   0   0   10

Cognition Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Cognition Therapeutics Inc together

PenkeI guess you are interested in Cognition Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cognition Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cognition Therapeutics Inc

I send you an email if I find something interesting about Cognition Therapeutics Inc.

Quick analysis of Cognition Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Cognition Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.63
Expected worth in 1 year
$0.22
How sure are you?
23.1%

+ What do you gain per year?

Total Gains per Share
$-0.40
Return On Investment
-21.0%

For what price can you sell your share?

Current Price per Share
$1.93
Expected price per share
$1.75 - $2.43
How sure are you?
50%

1. Valuation of Cognition Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$1.93

Intrinsic Value Per Share

$-8.46 - $-10.04

Total Value Per Share

$-7.83 - $-9.42

2. Growth of Cognition Therapeutics Inc (5 min.)




Is Cognition Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$24.4m$43m-$12.1m-39.4%

How much money is Cognition Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.7m$189.2k-$5.9m-103.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cognition Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#556 / 1010

Most Revenue
#949 / 1010

Most Profit
#456 / 1010

Most Efficient
#415 / 1010

What can you expect buying and holding a share of Cognition Therapeutics Inc? (5 min.)

Welcome investor! Cognition Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Cognition Therapeutics Inc.

What can you expect buying and holding a share of Cognition Therapeutics Inc?

First you should know what it really means to hold a share of Cognition Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Cognition Therapeutics Inc is $1.93. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cognition Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cognition Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.63. Based on the TTM, the Book Value Change Per Share is $-0.10 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cognition Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-10.8%-0.17-8.6%-0.13-7.0%-0.13-6.6%-0.13-6.6%
Usd Book Value Change Per Share-0.11-5.9%-0.10-5.2%-0.07-3.7%0.052.5%0.052.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.11-5.9%-0.10-5.2%-0.07-3.7%0.052.5%0.052.5%
Usd Price Per Share1.85-1.78-2.22-1.71-1.71-
Price to Earnings Ratio-2.22--2.80--4.42--2.85--2.85-
Price-to-Total Gains Ratio-16.21--23.72-3.16--8.94--8.94-
Price to Book Ratio2.95-2.28-2.00-1.69-1.69-
Price-to-Total Gains Ratio-16.21--23.72-3.16--8.94--8.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.93
Number of shares518
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.100.05
Usd Total Gains Per Share-0.100.05
Gains per Quarter (518 shares)-52.3825.00
Gains per Year (518 shares)-209.52100.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-210-220010090
20-419-4300200190
30-629-6400300290
40-838-8500400390
50-1048-10600500490
60-1257-12700600590
70-1467-14800700690
80-1676-16900800790
90-1886-19000900890
100-2095-211001000990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%3.010.00.023.1%3.010.00.023.1%3.010.00.023.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%3.010.00.023.1%3.010.00.023.1%3.010.00.023.1%

Fundamentals of Cognition Therapeutics Inc

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Fundamental data was last updated by Penke on 2024-04-21 22:54:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cognition Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cognition Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cognition Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y--436.8%+436.8%
10Y--597.3%+597.3%
1.1.2. Return on Assets

Shows how efficient Cognition Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • -23.2% Return on Assets means that Cognition Therapeutics Inc generated $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cognition Therapeutics Inc:

  • The MRQ is -23.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.2%TTM-14.7%-8.5%
TTM-14.7%YOY0.8%-15.5%
TTM-14.7%5Y-9.6%-5.1%
5Y-9.6%10Y-9.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.2%-13.3%-9.9%
TTM-14.7%-12.8%-1.9%
YOY0.8%-11.6%+12.4%
5Y-9.6%-13.8%+4.2%
10Y-9.6%-15.6%+6.0%
1.1.3. Return on Equity

Shows how efficient Cognition Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • -33.3% Return on Equity means Cognition Therapeutics Inc generated $-0.33 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cognition Therapeutics Inc:

  • The MRQ is -33.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.3%TTM-19.9%-13.3%
TTM-19.9%YOY1.2%-21.1%
TTM-19.9%5Y-6.9%-13.1%
5Y-6.9%10Y-6.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.3%-16.9%-16.4%
TTM-19.9%-16.1%-3.8%
YOY1.2%-14.9%+16.1%
5Y-6.9%-19.3%+12.4%
10Y-6.9%-20.1%+13.2%

1.2. Operating Efficiency of Cognition Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cognition Therapeutics Inc is operating .

  • Measures how much profit Cognition Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cognition Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y--486.2%+486.2%
10Y--628.4%+628.4%
1.2.2. Operating Ratio

Measures how efficient Cognition Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cognition Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y-5.679-5.679
10Y-7.823-7.823

1.3. Liquidity of Cognition Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cognition Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.37 means the company has $3.37 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cognition Therapeutics Inc:

  • The MRQ is 3.365. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.682. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.365TTM4.682-1.317
TTM4.682YOY6.285-1.603
TTM4.6825Y4.754-0.072
5Y4.75410Y4.7540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3653.863-0.498
TTM4.6824.169+0.513
YOY6.2855.337+0.948
5Y4.7546.122-1.368
10Y4.7546.434-1.680
1.3.2. Quick Ratio

Measures if Cognition Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.07 means the company can pay off $3.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cognition Therapeutics Inc:

  • The MRQ is 3.068. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.423. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.068TTM4.423-1.354
TTM4.423YOY6.040-1.617
TTM4.4235Y4.540-0.118
5Y4.54010Y4.5400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0683.504-0.436
TTM4.4233.991+0.432
YOY6.0405.371+0.669
5Y4.5406.088-1.548
10Y4.5406.395-1.855

1.4. Solvency of Cognition Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cognition Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cognition Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Cognition Therapeutics Inc assets are financed with 30.4% credit (debt) and the remaining percentage (100% - 30.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cognition Therapeutics Inc:

  • The MRQ is 0.304. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.248. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.304TTM0.248+0.056
TTM0.248YOY0.202+0.047
TTM0.2485Y2.380-2.132
5Y2.38010Y2.3800.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3040.339-0.035
TTM0.2480.337-0.089
YOY0.2020.271-0.069
5Y2.3800.368+2.012
10Y2.3800.388+1.992
1.4.2. Debt to Equity Ratio

Measures if Cognition Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 43.7% means that company has $0.44 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cognition Therapeutics Inc:

  • The MRQ is 0.437. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.333. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.437TTM0.333+0.104
TTM0.333YOY0.256+0.077
TTM0.3335Y0.193+0.140
5Y0.19310Y0.1930.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4370.392+0.045
TTM0.3330.403-0.070
YOY0.2560.335-0.079
5Y0.1930.427-0.234
10Y0.1930.461-0.268

2. Market Valuation of Cognition Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cognition Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Cognition Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.22 means the investor is paying $-2.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cognition Therapeutics Inc:

  • The EOD is -2.311. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.216. Based on the earnings, the company is expensive. -2
  • The TTM is -2.800. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.311MRQ-2.216-0.096
MRQ-2.216TTM-2.800+0.584
TTM-2.800YOY-4.423+1.623
TTM-2.8005Y-2.851+0.051
5Y-2.85110Y-2.8510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.311-2.300-0.011
MRQ-2.216-2.656+0.440
TTM-2.800-2.718-0.082
YOY-4.423-4.145-0.278
5Y-2.851-6.258+3.407
10Y-2.851-6.315+3.464
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cognition Therapeutics Inc:

  • The EOD is -3.430. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.288. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.613. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.430MRQ-3.288-0.142
MRQ-3.288TTM-4.613+1.325
TTM-4.613YOY-175.137+170.525
TTM-4.6135Y8.747-13.359
5Y8.74710Y8.7470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.430-2.974-0.456
MRQ-3.288-3.306+0.018
TTM-4.613-3.508-1.105
YOY-175.137-5.613-169.524
5Y8.747-8.378+17.125
10Y8.747-8.873+17.620
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cognition Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.95 means the investor is paying $2.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cognition Therapeutics Inc:

  • The EOD is 3.076. Based on the equity, the company is fair priced.
  • The MRQ is 2.948. Based on the equity, the company is underpriced. +1
  • The TTM is 2.281. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.076MRQ2.948+0.127
MRQ2.948TTM2.281+0.667
TTM2.281YOY1.999+0.282
TTM2.2815Y1.687+0.594
5Y1.68710Y1.6870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.0761.914+1.162
MRQ2.9482.116+0.832
TTM2.2812.097+0.184
YOY1.9992.881-0.882
5Y1.6873.550-1.863
10Y1.6873.936-2.249
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cognition Therapeutics Inc.

3.1. Institutions holding Cognition Therapeutics Inc

Institutions are holding 34.193% of the shares of Cognition Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Pathstone Holdings LLC5.65480.0219220537722053770
2023-09-30Pathstone Family Office, LLC5.65480.0242220537700
2023-12-31AIGH Capital Management, LLC5.22781.4922203885300
2023-12-31Vanguard Group Inc1.85010721554346585.0456
2023-12-31Worth Venture Partners, LLC1.30440.508650871900
2023-12-31Carlson Capital LP0.61030.0352238000-52000-17.931
2023-12-31Kestra Advisory Services, LLC0.56260.00332194344065022.7369
2023-12-31American Financial Group Inc0.52560.139420500000
2023-12-31Geode Capital Management, LLC0.4482017479800
2023-12-31Mercer Global Advisors Inc.0.33580.0007130951115000720.9579
2023-12-31Twin Focus Capital Partners, LLC0.23940.015693372933720
2023-12-31Commonwealth Equity Services Inc0.23780.00039273000
2023-12-31Bridgeway Capital Management, LLC0.23380.0036912002500037.7644
2023-12-31BlackRock Inc0.1426055609-624-1.1097
2023-12-31Texas Capital Bank Wealth Management Services Inc0.1420.012155395553950
2023-12-31FCA Corp0.1320.03275147100
2023-12-31State Street Corporation0.130105075000
2023-12-31CASTLE WEALTH MANAGEMENT LLC0.11120.04814338000
2023-09-30Steward Financial Group LLC0.10480.018440874408740
2023-12-31HighTower Advisors, LLC0.08450.00013296200
Total 23.73262.35649255806+2557702+27.6%

3.2. Funds holding Cognition Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.71560.000166908300
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr0.50390.000319654114170.7262
2024-02-29Fidelity Extended Market Index0.25890.0005100964-489-0.482
2023-12-31Bridgeway Ultra-Small Company Market0.23380.0908912002500037.7644
2024-03-28iShares Micro-Cap ETF0.13260.01025171100
2024-02-29Fidelity Series Total Market Index0.06180.00012408600
2024-02-29Fidelity Total Market Index0.05630.00012196800
2024-03-31Vanguard Balanced Index Inv0.04980.000119437194370
2024-03-31NT Ext Equity Mkt Idx Fd - L0.04890.00061905900
2023-12-31Northern Trust Extended Eq Market Idx0.04890.00061905900
2024-02-29Spartan Total Market Index Pool E0.03970.00011548700
2024-02-29Fidelity Nasdaq Composite Index0.03530.00021376300
2024-03-31Vanguard U.S. Eq Idx £ Acc0.03240.00011263500
2024-03-31Schwab Total Stock Market Index0.03070.00011196500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0260.00031012500
2024-02-29Spartan Extended Market Index Pool E0.02260.000787984895.8852
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02090.00038132150.1848
2024-02-291290 VT Micro Cap K0.01050.0058410900
2023-12-31BNYM Mellon SL Market Completion UC10.00680.00112642-42-1.5648
2024-03-31State St US Extended Mkt Indx NL Cl C0.00440.0002170000
Total 3.33980.11231302464+45827+3.5%

3.3. Insider Transactions

Insiders are holding 6.504% of the shares of Cognition Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-14Lisa RicciardiBUY57001.75

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cognition Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.114-0.101-11%-0.071-38%0.048-336%0.048-336%
Book Value Per Share--0.6280.792-21%1.104-43%0.080+683%0.080+683%
Current Ratio--3.3654.682-28%6.285-46%4.754-29%4.754-29%
Debt To Asset Ratio--0.3040.248+23%0.202+51%2.380-87%2.380-87%
Debt To Equity Ratio--0.4370.333+31%0.256+71%0.193+126%0.193+126%
Dividend Per Share----0%-0%-0%-0%
Eps---0.209-0.165-21%-0.134-36%-0.128-39%-0.128-39%
Free Cash Flow Per Share---0.141-0.104-26%-0.120-15%-0.077-45%-0.077-45%
Free Cash Flow To Equity Per Share---0.078-0.075-4%-0.084+8%0.049-260%0.049-260%
Gross Profit Margin--0.9920.998-1%1.000-1%0.999-1%0.999-1%
Intrinsic Value_10Y_max---10.043--------
Intrinsic Value_10Y_min---8.455--------
Intrinsic Value_1Y_max---0.428--------
Intrinsic Value_1Y_min---0.420--------
Intrinsic Value_3Y_max---1.727--------
Intrinsic Value_3Y_min---1.639--------
Intrinsic Value_5Y_max---3.557--------
Intrinsic Value_5Y_min---3.263--------
Market Cap75270386.000+4%72150370.00069225355.000+4%86385443.000-16%66840342.769+8%66840342.769+8%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio3.076+4%2.9482.281+29%1.999+48%1.687+75%1.687+75%
Pe Ratio-2.311-4%-2.216-2.800+26%-4.423+100%-2.851+29%-2.851+29%
Price Per Share1.930+4%1.8501.775+4%2.215-16%1.714+8%1.714+8%
Price To Free Cash Flow Ratio-3.430-4%-3.288-4.613+40%-175.137+5227%8.747-138%8.747-138%
Price To Total Gains Ratio-16.907-4%-16.206-23.718+46%3.159-613%-8.939-45%-8.939-45%
Quick Ratio--3.0684.423-31%6.040-49%4.540-32%4.540-32%
Return On Assets---0.232-0.147-37%0.008-3029%-0.096-59%-0.096-59%
Return On Equity---0.333-0.199-40%0.012-2935%-0.069-79%-0.069-79%
Total Gains Per Share---0.114-0.101-11%-0.071-38%0.048-336%0.048-336%
Usd Book Value--24474000.00030892250.000-21%43052000.000-43%3124000.000+683%3124000.000+683%
Usd Book Value Change Per Share---0.114-0.101-11%-0.071-38%0.048-336%0.048-336%
Usd Book Value Per Share--0.6280.792-21%1.104-43%0.080+683%0.080+683%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.209-0.165-21%-0.134-36%-0.128-39%-0.128-39%
Usd Free Cash Flow---5486000.000-4041250.000-26%-4676000.000-15%-3000538.462-45%-3000538.462-45%
Usd Free Cash Flow Per Share---0.141-0.104-26%-0.120-15%-0.077-45%-0.077-45%
Usd Free Cash Flow To Equity Per Share---0.078-0.075-4%-0.084+8%0.049-260%0.049-260%
Usd Market Cap75270386.000+4%72150370.00069225355.000+4%86385443.000-16%66840342.769+8%66840342.769+8%
Usd Price Per Share1.930+4%1.8501.775+4%2.215-16%1.714+8%1.714+8%
Usd Profit---8141000.000-5749250.000-29%189250.000-4402%-2755692.308-66%-2755692.308-66%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.114-0.101-11%-0.071-38%0.048-336%0.048-336%
 EOD+5 -3MRQTTM+4 -26YOY+3 -275Y+8 -2210Y+8 -22

4.2. Fundamental Score

Let's check the fundamental score of Cognition Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.311
Price to Book Ratio (EOD)Between0-13.076
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.068
Current Ratio (MRQ)Greater than13.365
Debt to Asset Ratio (MRQ)Less than10.304
Debt to Equity Ratio (MRQ)Less than10.437
Return on Equity (MRQ)Greater than0.15-0.333
Return on Assets (MRQ)Greater than0.05-0.232
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cognition Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.729
Ma 20Greater thanMa 501.939
Ma 50Greater thanMa 1001.936
Ma 100Greater thanMa 2001.971
OpenGreater thanClose1.930
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  1,7321031,835-4101,4253301,755-1,7550



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets35,163
Total Liabilities10,689
Total Stockholder Equity24,474
 As reported
Total Liabilities 10,689
Total Stockholder Equity+ 24,474
Total Assets = 35,163

Assets

Total Assets35,163
Total Current Assets34,222
Long-term Assets941
Total Current Assets
Cash And Cash Equivalents 29,922
Net Receivables 1,281
Other Current Assets 3,019
Total Current Assets  (as reported)34,222
Total Current Assets  (calculated)34,222
+/-0
Long-term Assets
Property Plant Equipment 941
Long-term Assets Other 0
Long-term Assets  (as reported)941
Long-term Assets  (calculated)941
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,169
Long-term Liabilities520
Total Stockholder Equity24,474
Total Current Liabilities
Short-term Debt 174
Short Long Term Debt 544
Accounts payable 3,695
Other Current Liabilities 4,599
Total Current Liabilities  (as reported)10,169
Total Current Liabilities  (calculated)9,012
+/- 1,157
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt520
Long-term Liabilities  (as reported)520
Long-term Liabilities  (calculated)520
+/- 0
Total Stockholder Equity
Common Stock32
Retained Earnings -141,189
Accumulated Other Comprehensive Income -195
Other Stockholders Equity 165,826
Total Stockholder Equity (as reported)24,474
Total Stockholder Equity (calculated)24,474
+/-0
Other
Capital Stock32
Cash and Short Term Investments 29,922
Common Stock Shares Outstanding 30,777
Current Deferred Revenue1,701
Liabilities and Stockholders Equity 35,163
Net Debt -29,748
Net Invested Capital 25,018
Net Working Capital 24,053
Property Plant and Equipment Gross 1,990
Short Long Term Debt Total 174



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
7,119
16,512
17,289
13,389
59,137
58,696
52,812
53,557
50,425
45,663
43,960
38,772
35,163
35,16338,77243,96045,66350,42553,55752,81258,69659,13713,38917,28916,5127,119000
   > Total Current Assets 
0
0
0
6,908
15,952
14,683
10,038
58,992
56,440
50,743
50,932
47,647
42,801
41,551
36,040
34,222
34,22236,04041,55142,80147,64750,93250,74356,44058,99210,03814,68315,9526,908000
       Cash And Cash Equivalents 
0
0
0
5,189
13,373
11,300
8,310
54,721
51,509
45,771
46,610
41,562
38,810
37,190
32,969
29,922
29,92232,96937,19038,81041,56246,61045,77151,50954,7218,31011,30013,3735,189000
       Net Receivables 
0
0
0
1,152
2,317
2,552
1,147
2,266
2,794
3,295
2,528
3,672
1,609
2,393
1,638
1,281
1,2811,6382,3931,6093,6722,5283,2952,7942,2661,1472,5522,3171,152000
       Other Current Assets 
0
0
0
23
27
65
10
11
2,137
1,677
1,794
2,413
2,382
1,968
1,433
3,019
3,0191,4331,9682,3822,4131,7941,6772,1371110652723000
   > Long-term Assets 
0
0
0
211
560
2,606
3,351
145
2,256
2,069
2,625
2,778
2,862
2,409
2,732
941
9412,7322,4092,8622,7782,6252,0692,2561453,3512,606560211000
       Property Plant Equipment 
0
0
0
211
188
165
141
145
839
784
937
1,046
1,027
984
977
941
9419779841,0271,046937784839145141165188211000
       Other Assets 
0
0
0
0
372
2,441
3,210
0
1,417
0
1,688
0
0
1,425
0
0
001,425001,68801,41703,2102,4413720000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
3,210
0
0
0
0
0
0
0
0
0
0000000003,210000000
> Total Liabilities 
0
0
0
75,303
84,366
100,971
100,107
7,864
9,956
8,913
14,237
10,176
9,880
9,574
9,846
10,689
10,6899,8469,5749,88010,17614,2378,9139,9567,864100,107100,97184,36675,303000
   > Total Current Liabilities 
0
0
0
3,250
4,338
6,224
4,428
7,864
7,645
6,818
12,116
7,795
7,465
7,914
8,229
10,169
10,1698,2297,9147,4657,79512,1166,8187,6457,8644,4286,2244,3383,250000
       Short-term Debt 
0
0
0
0
0
0
0
0
949
563
114
783
584
383
172
174
17417238358478311456394900000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
799
402
0
634
427
217
2
544
5442217427634040279900000000
       Accounts payable 
0
0
0
2,003
3,187
3,657
2,775
4,168
3,997
3,304
8,087
3,216
3,120
4,060
2,859
3,695
3,6952,8594,0603,1203,2168,0873,3043,9974,1682,7753,6573,1872,003000
       Other Current Liabilities 
0
0
0
1,247
1,151
2,567
1,653
3,696
1,383
1,667
2,314
2,094
2,115
2,415
4,288
4,599
4,5994,2882,4152,1152,0942,3141,6671,3833,6961,6532,5671,1511,247000
   > Long-term Liabilities 
0
0
0
72,053
80,028
94,747
95,679
4,168
2,311
2,095
2,121
2,381
2,415
1,660
1,617
520
5201,6171,6602,4152,3812,1212,0952,3114,16895,67994,74780,02872,053000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
3,210
0
0
0
0
0
0
0
0
0
0000000003,210000000
       Warrants
0
0
0
0
0
0
169,522
0
0
0
0
0
0
0
0
0
000000000169,522000000
       Other Liabilities 
0
0
0
0
11,967
9,986
10,918
0
1,865
1,691
1,518
0
0
1,052
0
0
001,052001,5181,6911,865010,9189,98611,9670000
       Deferred Long Term Liability 
0
0
0
0
372
2,441
3,210
0
0
0
0
0
0
0
0
0
0000000003,2102,4413720000
> Total Stockholder Equity
0
0
0
-68,184
-67,854
-83,682
-86,718
51,273
48,740
43,899
39,320
40,249
35,783
34,386
28,926
24,474
24,47428,92634,38635,78340,24939,32043,89948,74051,273-86,718-83,682-67,854-68,184000
   Common Stock
0
0
0
1
2
1
1
22
22
22
24
29
29
30
30
32
3230302929242222221121000
   Retained Earnings Total Equity00-126,299-121,573-115,401-110,219000-86,665000000
   Accumulated Other Comprehensive Income -195-196-196-195-199-201-200-197-198-196-193-192-187000
   Capital Surplus 
0
0
0
0
0
0
142
0
0
0
149,716
155,820
157,522
160,851
0
0
00160,851157,522155,820149,716000142000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
222
333
65
-4,474
145,453
146,757
147,671
149,716
155,820
157,522
160,851
162,140
165,826
165,826162,140160,851157,522155,820149,716147,671146,757145,453-4,47465333222000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-252
Gross Profit-252-252
 
Operating Income (+$)
Gross Profit-252
Operating Expense-50,472
Operating Income-50,724-50,724
 
Operating Expense (+$)
Research Development37,196
Selling General Administrative13,528
Selling And Marketing Expenses-252
Operating Expense50,47250,472
 
Net Interest Income (+$)
Interest Income0
Interest Expense--27
Other Finance Cost-55
Net Interest Income-28
 
Pretax Income (+$)
Operating Income-50,724
Net Interest Income-28
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-25,788-75,660
EBIT - interestExpense = -50,697
-25,788
-25,815
Interest Expense-27
Earnings Before Interest and Taxes (EBIT)-50,724-25,815
Earnings Before Interest and Taxes (EBITDA)-50,472
 
After tax Income (+$)
Income Before Tax-25,788
Tax Provision-0
Net Income From Continuing Ops-22,829-25,788
Net Income-25,788
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses50,724
Total Other Income/Expenses Net24,93628
 

Technical Analysis of Cognition Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cognition Therapeutics Inc. The general trend of Cognition Therapeutics Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cognition Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cognition Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.1599 < 2.28 < 2.43.

The bearish price targets are: 1.77 > 1.75 > 1.75.

Tweet this
Cognition Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cognition Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cognition Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cognition Therapeutics Inc. The current macd is -0.00258043.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cognition Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cognition Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cognition Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cognition Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCognition Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cognition Therapeutics Inc. The current adx is 22.17.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cognition Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cognition Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cognition Therapeutics Inc. The current sar is 1.7962.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cognition Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cognition Therapeutics Inc. The current rsi is 49.73. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Cognition Therapeutics Inc Daily Relative Strength Index (RSI) ChartCognition Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cognition Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cognition Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cognition Therapeutics Inc Daily Stochastic Oscillator ChartCognition Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cognition Therapeutics Inc. The current cci is -9.61248654.

Cognition Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCognition Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cognition Therapeutics Inc. The current cmo is -0.02291366.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cognition Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCognition Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cognition Therapeutics Inc. The current willr is -62.15193295.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cognition Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cognition Therapeutics Inc Daily Williams %R ChartCognition Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cognition Therapeutics Inc.

Cognition Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cognition Therapeutics Inc. The current atr is 0.14290014.

Cognition Therapeutics Inc Daily Average True Range (ATR) ChartCognition Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cognition Therapeutics Inc. The current obv is 17,151,451.

Cognition Therapeutics Inc Daily On-Balance Volume (OBV) ChartCognition Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cognition Therapeutics Inc. The current mfi is 44.34.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cognition Therapeutics Inc Daily Money Flow Index (MFI) ChartCognition Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cognition Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Cognition Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cognition Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.729
Ma 20Greater thanMa 501.939
Ma 50Greater thanMa 1001.936
Ma 100Greater thanMa 2001.971
OpenGreater thanClose1.930
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cognition Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Cognition Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cognition Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cognition Therapeutics Inc

I send you an email if I find something interesting about Cognition Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cognition Therapeutics Inc.

Receive notifications about Cognition Therapeutics Inc in your mailbox!